Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GT20029 in Healthy Subjects and Subjects with Androgenetic Alopecia or Acne
NCT05428449Phase 1Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gt20029 gel placebo in androgenetic alopecia (AGA) and acne vulgaris (2 arms), sponsored by Kintor Pharmaceutical Limited. Primary endpoints: Adverse event at 35 days, Skin irritation assessments at 35 days and 4 more. Started Feb 2022; status: completed.
02
Drugs
gt20029 gel placebo
03
Conditions
androgenetic alopecia (AGA)acne vulgaris
Beyond the preview
Go deeper on NCT05428449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428449.